Inactive Instrument

News Inotek Pharmaceuticals Corp Nasdaq

Equities

US45780V1026

End-of-day quote Nasdaq Other stock markets
-	-

Apr. 16	Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	MT
Apr. 11	Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Rocket Pharmaceuticals Insider Sold Shares Worth $1,945,785, According to a Recent SEC Filing	Apr. 16	MT
Rocket Pharmaceuticals Insider Sold Shares Worth $308,763, According to a Recent SEC Filing	Apr. 11	MT
Rocket Pharmaceuticals Says European Medicines Agency Accepted Marketing Authorization Application for RP-L102	Apr. 02	MT
Goldman Sachs Initiates Rocket Pharmaceuticals at Neutral With $39 Price Target	Apr. 02	MT
Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02	BU
Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia	Apr. 02	CI
Rocket Pharmaceuticals Appoints Aaron Ondrey as CFO	Mar. 26	MT
Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team	Mar. 26	BU
Rocket Pharmaceuticals, Inc. Announces Appointment of Aaron Ondrey as Chief Financial Officer	Mar. 26	CI
Rocket Pharmaceuticals, Inc. Announces Executive Appointments	Mar. 26	CI
Thinking about buying stock in Ocean Biomedical, CASI Pharmaceuticals, Cardiol Therapeutics, Geron, or Rocket Pharmaceuticals?	Mar. 05	PR
UBS Adjusts Rocket Pharmaceuticals Price Target to $54 From $56, Maintains Buy Rating	Mar. 01	MT
Rocket Pharmaceuticals Q4 Loss Narrows	Feb. 26	MT
Rocket Pharmaceuticals: Q4 Earnings Snapshot	Feb. 26	AQ
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	Feb. 26	BU
Rocket Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 25	CI
North American Morning Briefing : S&P 500 Futures -2-	Feb. 23	DJ
Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI for the Treatment of Severe Leukocyte Adhesion Deficiency-I	Feb. 14	AQ
Rocket Pharmaceuticals Says FDA Extends Review Timeline for Kresladi; Shares Decline	Feb. 13	MT
FDA Extends Review of Rocket Pharma's Proposed Kresladi	Feb. 13	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Inotek Pharmaceuticals Corp Nasdaq

Equities

US45780V1026

Summary

Filters